August 5, 2025 — Recursion (Nasdaq: RXRX) reported its second-quarter business updates and financial results, highlighting advancements in its platform and partnered programs. The company’s earnings call will be held on August 5, 2025, at 8:00 am ET, accessible via Recursion’s X, LinkedIn, and YouTube accounts.
CEO Chris Gibson noted the power of Recursion’s platform in discovering new medicines and identifying target patient populations. The company achieved its fourth partnered discovery milestone with Sanofi this quarter. Chief R&D Officer Najat Khan discussed progress with REC-1245 and REC-617, emphasizing data-driven patient selection.
Internal pipeline updates included REC-1245 (RBM39), with ongoing Phase 1/2 DAHLIA study updates, and REC-617 (CDK7), which has initiated a combination dose escalation portion of the ELUCIDATE Phase 1/2 trial. Recursion also acquired full rights to REC-102 (ENPP1) from its joint venture with Rallybio.
Partnered discovery updates noted Sanofi’s multi-target collaboration, which has achieved $130 million in upfront and milestone payments to date. Recursion continues to progress with Roche and Genentech on building neuromaps, as well as GI-oncology specific phenomaps. Bayer and Merck KgAa collaborations are ongoing.
The Recursion OS 2.0 platform continues to drive program development, incorporating the Boltz-2 open-source model. The company’s ClinTech platform is expanding to integrate patient datasets for strengthening programs.
Second quarter financial results revealed a cash position of $533.8 million as of June 30, 2025, with an expected cash runway into the fourth quarter of 2027. Total revenue was $19.2 million for the second quarter of 2025, compared to $14.4 million for the second quarter of 2024. Net loss was $171.9 million for the second quarter of 2025, compared to a net loss of $97.5 million for the second quarter of 2024.
Contact:
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Source: Recursion
